DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Research Programs
  3. Duchenne Muscular Dystrophy
  4. Research Highlights/News
  5. 2021 Duchenne Muscular Dystrophy Research Program

Duchenne Muscular Dystrophy

NEWS RELEASE

Released: April 28, 2021

Defense Health Program
Department of Defense Duchenne Muscular Dystrophy Research Program
Anticipated Funding Opportunities for Fiscal Year 2021 (FY21)

The FY21 Defense Appropriations Act provides funding to the Department of Defense Duchenne Muscular Dystrophy Research Program (DMDRP) to support research addressing Duchenne pathobiology and discovery and development of therapeutics, related devices and tools. The managing agent for the anticipated program announcements/funding opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

The DMDRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY21 funding opportunities. This pre-announcement should not be construed as an obligation by the government. The FY21 DMDRP program announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the program announcements are released.

Award Mechanism Eligibility Key Mechanism Elements Funding
Idea Development Award Established Investigators: Independent investigators at or above the level of Assistant Professor (or equivalent); or

New Investigators: Investigators that meet the following criteria by the application submission deadline date:

  • Have not previously received a DMDRP Idea Development Award
  • Are within 10 years of first faculty appointment (or equivalent)
  • Supports the development of innovative, high-impact ideas that advance the understanding of Duchenne muscular dystrophy (DMD) and ultimately lead to improved outcomes.
  • Must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that address primary pathology of DMD. Eligible therapeutic strategies include: gene therapy, genome editing, oligonucleotide therapies, exon skipping, protein therapeutics, and cell therapies. Therapies that will be efficacious across the life-span, particularly in adolescents and adults are encouraged.
  • Preliminary data required.
  • Clinical trials or applications including a clinical trial aim are not allowed.
  • Maximum funding of $350,000 in direct costs (plus indirect costs).
  • Maximum period of performance is 2 years.
Translational Research Award

New for FY21

 Investigators at or above the level of Assistant Professor (or equivalent).
  • Supports translational studies that have moved beyond the realm of basic research and have the potential to result in a near-term impact in clinical research or the clinic.
  • Research projects investigating therapies that will be efficacious across the life-span, particularly in adolescents and adults are strongly encouraged.
  • Preliminary data required.
  • Clinical trials are allowed.
  • Maximum funding of $1,300,000 in direct costs (plus indirect costs).
  • Maximum period of performance is 3 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final program announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the program announcements are released. For email notification when program announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the DMDRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


Last updated Thursday, December 5, 2024